{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470632689
| IUPAC_name = (''RS'')-''N''-(2-<nowiki/>{[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)morpholine-4-carboxamide
| image = Xamoterol.svg
| width = 300

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 81801-12-9
| ATC_prefix = C01
| ATC_suffix = CX07
| PubChem = 155774
| IUPHAR_ligand = 538
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 137213
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7HE0JQL703
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06328
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 75753

<!--Chemical data-->
| C=16 | H=25 | N=3 | O=5 
| molecular_weight = 339.387 g/mol
| smiles = O=C(NCCNCC(O)COc1ccc(O)cc1)N2CCOCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DXPOSRCHIDYWHW-UHFFFAOYSA-N
}}

'''Xamoterol''' is a [[cardiac stimulant]]. It works by binding to the [[Beta-1 adrenergic receptor|β<sub>1</sub> adrenergic receptor]]. It is a 3rd generation adrenergic β receptor [[partial agonist]].<ref>{{cite journal|last1=Marlow|first1=HF|title=Xamoterol, a β<sub>1</sub>-adrenoceptor partial agonist: review of the clinical efficacy in heart failure|journal=British Journal of Clinical Pharmacology|date=1989|volume=28 Suppl 1|pages=23S–30S|pmid=2572251|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379873/pdf/brjclinpharm00077-0024.pdf|pmc=1379873|accessdate=6 March 2016|doi=10.1111/j.1365-2125.1989.tb03570.x}}</ref> It provides cardiac stimulation at rest but it acts as a blocker during exercise.<ref>{{cite book|last1=Rang|first1=H.P.|last2=Dale|first2=M.M.|last3=Ritter|first3=J.M.|last4=Moore|first4=P.K.|title=Pharmacology|date=1999|publisher=Churchill Livingstone|location=Edinburgh; New York|isbn=0443059748|page=163|edition=5th}}</ref>

==References==
{{reflist}}

{{Adrenergic agonists}}
{{Cardiac stimulants excluding cardiac glycosides }}

[[Category:Beta1-adrenergic agonists]]
[[Category:Cardiac stimulants]]
[[Category:Inotropic agents]]
[[Category:Morpholines]]
[[Category:Phenol ethers]]
[[Category:Phenols]]


{{cardiovascular-drug-stub}}